Immuneering presented preclinical data at SITC2026 showing atebimetinib could enhance PD-1 checkpoint blockade in RAS-mutant tumor models. The update builds on

Immuneering presented preclinical data at SITC2026 showing atebimetinib could enhance PD-1 checkpoint blockade in RAS-mutant tumor models. The update builds on earlier pancreatic, thyroid and broader RAS-mutant cancer findings as development continues.